What is Chimerix?
Chimerix, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of therapeutics addressing critical unmet medical needs, primarily in the United States. The company's lead candidate, brincidofovir, is an investigational nucleoside analog designed for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients, and for treating severe adenovirus infection, smallpox, and BK virus infection in transplant patients. Chimerix is also advancing other candidates, including CMX521 for norovirus and CMX157 for HIV and hepatitis B virus infection, signaling a broad commitment to combating viral diseases. The company's strategic partnerships, including agreements with ContraVir Pharmaceuticals and BARDA, highlight its collaborative approach to drug development and commercialization.
How much funding has Chimerix raised?
Chimerix has raised a total of $237.9M across 8 funding rounds:
Series A
$1M
Series B
$3.1M
Unspecified
$36.1M
Series C
$11M
Series D
$23.1M
Other Financing Round
$16.1M
Other Financing Round
$45M
Stock Offering
$102.5M
Series A (2002): $1M with participation from Asset Management Company
Series B (2003): $3.1M led by Sanderling Ventures
Unspecified (2003): $36.1M supported by National Institutes of Health
Series C (2004): $11M featuring Sanderling Ventures
Series D (2007): $23.1M backed by Canaan Partners, Frazier Healthcare Partners, Alta Partners, and Sanderling Ventures
Other Financing Round (2009): $16.1M with participation from Canaan Partners, Alta Partners, and Sanderling Ventures
Other Financing Round (2011): $45M led by Canaan Partners, Frazier Healthcare Partners, New Leaf Venture Partners, Morningside Group, Pappas Ventures, Alta Partners, and Sanderling Ventures
Stock Issuance/Offering (2013): $102.5M, investors not publicly disclosed
Key Investors in Chimerix
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm founded in 1979, specializing in building new biomedical companies. The firm has supported over 90 biomedical companies, focusing on early-stage financing and active management to achieve high rates of return for both entrepreneurs and investors. Their investment areas include small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices. Sanderling Ventures is dedicated to fostering close partnerships with entrepreneurs to create significant companies in the biomedical sector.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health. With offices in the U.S. and Israel and billions of dollars under management, Canaan has funded hundreds of startups and supported dozens of IPOs and acquisitions.
Frazier Healthcare Partners
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.
What's next for Chimerix?
With a substantial total funding base of $237.9M and a recent major strategic investment of $102.5M, Chimerix is positioned for accelerated growth and pipeline advancement. The company's focus on serious viral infections, particularly in vulnerable patient populations, aligns with significant market opportunities and public health priorities. Future strategic moves will likely involve advancing clinical trials for brincidofovir and other candidates, potentially seeking regulatory approvals, and expanding its commercialization efforts. The sustained investment from prominent venture capital firms indicates strong confidence in Chimerix's scientific approach and market potential, suggesting a trajectory towards becoming a key player in the antiviral therapeutics sector.
See full Chimerix company page
